Clinical trial
Arsenic Trioxide in Treating Patients With Recurrent or Refractory Acute…
NCT00003885 · Our Lady of Mercy Medical Center, Other · Unknown status
Key facts
| NCT number | NCT00003885 |
|---|---|
| Title | Arsenic Trioxide in Treating Patients With Recurrent or Refractory Acute Leukemia, Chronic Myeloide Leukemia, Myelodysplasia, Lymphoma, or Myeloma |
| Official title | Phase II Study of Arsenic Trioxide in Relapsed/Refractory Acute Leukemia and Blast Crisis of Chronic Myeloid Leukemia |
| Lead sponsor | Our Lady of Mercy Medical Center, Other |
| Status | Unknown status |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes |
| Intervention type | Drug |
| Interventions | arsenic trioxide |
| Enrollment | 60 |
| Start date | Nov 1, 1997 |
| First posted | Aug 18, 2004 |
| Last update posted | Nov 6, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: